Cancer-nutrition research moves fast — genuinely new findings arrive most months. This is where Dr. Kanuru writes directly, translating current, credible research into plain language: what's genuinely promising, what's overhyped, and what's still an open question.
The FDA's Oncology AI Program is already approving clinical algorithms. What the regulatory engagement tells us about where oncology AI is heading — and why the sceptic's question needs to change.
Read article →AI can recognise patterns in cancer. The more important question is how capability becomes clinical value — and why that distinction will define the next chapter of oncology AI.
Read article →Care is delivered by department; biology operates as one system. AI second-opinion tools can help close that gap — flagging supplement interactions, benchmarking treatment plans, and giving patients a stronger footing with their care team.
Read article →